Direkt zum Inhalt
Merck
  • Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.

Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.

Journal of medicinal chemistry (2003-09-05)
J Scott Sawyer, Bryan D Anderson, Douglas W Beight, Robert M Campbell, Michael L Jones, David K Herron, John W Lampe, Jefferson R McCowan, William T McMillen, Nicholas Mort, Stephen Parsons, Edward C R Smith, Michal Vieth, Leonard C Weir, Lei Yan, Faming Zhang, Jonathan M Yingling
ZUSAMMENFASSUNG

Pyrazole-based inhibitors of the transforming growth factor-beta type I receptor kinase domain (TbetaR-I) are described. Examination of the SAR in both enzyme- and cell-based in vitro assays resulted in the emergence of two subseries featuring differing selectivity versus p38 MAP kinase. A common binding mode at the active site has been established by successful cocrystallization and X-ray analysis of potent inhibitors with the TbetaR-I receptor kinase domain.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
LY-364947, ≥98% (HPLC)